This World AIDS Day, we mark 40 years since the first HIV case was identified. The most important takeaway is that there is still further to go to prevent new infections and treat the millions of people living with HIV/AIDS today.
Read moreIFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
Brussels/Geneva 26 November – The European Commission and the European and international associations representing the innovative biopharmaceutical industries are exploring the opportunities, challenges and possible avenues to create stronger vaccine and treatment manufacturing capabilities in Africa. The European Union has identified the strengthening of health industries in Africa as being a critical objective to increase...
Read moreThe World Health Assembly Special Session on a Pandemic Treaty, which will convene health ministries from around the world in Geneva next week, offers a unique opportunity to take a look back and share some important lessons learnt from fighting the COVID-19 pandemic.
Read moreIFPMA welcomes the opportunity to contribute to the Special Session of the World Health Assembly in this unique and unprecedented moment to take lessons learned from fighting COVID-19 into tackling future global health crises. The COVID response has revealed to all the value of the rapid development and manufacture of vaccines and treatments, the importance...
Read moreOn World Antimicrobial Awareness Week (WAAW) the International Alliance of Patients’ Organizations (IAPO), the IAPO Patients for Patient Safety Observatory and its AMR Patient Alliance, International Council of Nurses (ICN), International Pharmaceutical Federation (FIP), International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the Union for International Cancer Control (UICC), responding to the call to...
Read moreAMR is a serious and increasing threat to global health security and threatens much of the modern medicine we have come to rely on, made possible by our ability to prevent and treat infections.
Read more
Sometimes dubbed the “silent pandemic,” Antimicrobial Resistance (AMR) is a natural phenomenon that occurs when microorganisms such as bacteria adapt after repeated exposure to antibiotics, rendering treatments ineffective. It has been at the top of the global health agenda for many years, and young professionals in healthcare are acutely aware of it.
Read moreFor a long time, the world has recognised the threat posed by antimicrobial resistance (AMR) but the pipeline of new antibiotics to tackle it remains too weak. The WHO has recognised AMR as one of the urgent health challenges of the decade. But, while we have seen progress in tackling this looming catastrophe in some areas,...
Read moreAMR is a silent pandemic that needs attention now. Globally, we need to take action or it will continue to claim lives.
Read more17 November 2021 – Innovative biopharmaceutical companies, represented by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), welcome the publication of the World Health Organization’s (WHO) latest report “Keeping the 100-year-old promise: making insulin access universal”. We fully agree that diabetes is a global health priority and that major gaps in access to quality...
Read moreNovember 17, 2021, Berlin – Ahead of the “World Antimicrobial Awareness Week” (November 18-24) 20 national and international organizations from academia, healthcare and the pharmaceutical industry appealed today to G7 governments to step up efforts to tackle the problem of growing antibiotic resistance. In a joint statement, they stress that only an approach involving both the...
Read more